Safety and tolerability of PARP inhibitors in cancer patients: a network meta-analysis of randomized controlled trials
{{output}}
Background: Poly(ADP-ribose) polymerase inhibitors (PARPi) for the treatment of homologous recombination (HR)-deficient cancers have revolutionized cancer treatment in recent years. Despite documented clinical benefits, the use o... ...
